Q1 Earnings Estimate for Liquidia Issued By HC Wainwright

Liquidia Co. (NASDAQ:LQDA) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for Liquidia in a report released on Thursday, March 20th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.49) per share for the quarter. HC Wainwright has a “Buy” rating and a $29.00 price objective on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Liquidia’s FY2025 earnings at ($1.53) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.47) EPS and FY2028 earnings at ($0.07) EPS.

Several other analysts have also recently commented on LQDA. Needham & Company LLC boosted their price target on Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday. Wells Fargo & Company began coverage on shares of Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 target price on the stock. Finally, Scotiabank increased their target price on shares of Liquidia from $30.00 to $34.00 and gave the company a “sector outperform” rating in a research report on Thursday. One analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $26.63.

Liquidia Trading Down 2.1 %

NASDAQ:LQDA opened at $15.12 on Monday. The stock has a 50 day moving average of $14.79 and a two-hundred day moving average of $12.23. Liquidia has a 12 month low of $8.26 and a 12 month high of $16.92. The firm has a market cap of $1.28 billion, a P/E ratio of -9.28 and a beta of 0.07.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The company had revenue of $2.92 million for the quarter, compared to analyst estimates of $4.60 million.

Hedge Funds Weigh In On Liquidia

Several large investors have recently modified their holdings of LQDA. Corebridge Financial Inc. increased its position in shares of Liquidia by 2.3% during the 4th quarter. Corebridge Financial Inc. now owns 31,516 shares of the company’s stock worth $371,000 after purchasing an additional 694 shares during the last quarter. Catalina Capital Group LLC increased its position in shares of Liquidia by 6.5% during the fourth quarter. Catalina Capital Group LLC now owns 18,307 shares of the company’s stock valued at $215,000 after acquiring an additional 1,125 shares during the last quarter. Cetera Investment Advisers increased its position in shares of Liquidia by 4.3% during the fourth quarter. Cetera Investment Advisers now owns 31,243 shares of the company’s stock valued at $367,000 after acquiring an additional 1,277 shares during the last quarter. Summit Investment Advisors Inc. raised its stake in shares of Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock valued at $78,000 after acquiring an additional 1,719 shares during the period. Finally, Sigma Planning Corp lifted its holdings in shares of Liquidia by 3.4% in the 4th quarter. Sigma Planning Corp now owns 65,210 shares of the company’s stock worth $767,000 after acquiring an additional 2,115 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Insider Activity at Liquidia

In related news, General Counsel Russell Schundler sold 16,393 shares of the company’s stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $193,109.54. Following the transaction, the general counsel now directly owns 573,478 shares in the company, valued at approximately $6,755,570.84. This represents a 2.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Rajeev Saggar sold 2,445 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total value of $31,785.00. Following the sale, the insider now directly owns 267,943 shares of the company’s stock, valued at approximately $3,483,259. This trade represents a 0.90 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,245 shares of company stock valued at $843,326. 30.10% of the stock is owned by company insiders.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).